RightFit
RecruitingNot applicable

Mindfulness to Enhance Cognitive Health in Latino Older Adults

Mindfulness to Enhance Cognitive Health in Latinx Older Adults

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
65 Years and older
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Blood draws

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Finally, all participants will complete a blood draw at the end of the study to determine AD biomarker status."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether mindfulness training, which teaches people to focus on the present moment, may support memory and thinking and lower the risk of Alzheimer's disease. It is for Hispanic/Latino adults age 65 and older. The study also looks at how mindfulness may help.

The primary objective of the proposed research is to investigate the promise and underlying mechanisms of mindfulness training as a preventative lifestyle intervention to enhance cognitive health in Latino older adults, thereby mitigating risk of Alzheimer's Disease (AD) in a population that may be particularly vulnerable.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are Hispanic/Latino.
  • You are age 65 or older.
  • People of any gender may join.
  • You live in the community, rather than in a care facility.
  • Your health is stable, and you are willing to take part in study activities.
  • You have not had a lot of mindfulness training.

Who can't join

  • You have an unstable mental health condition that needs treatment right away.
  • You have a health condition that may greatly shorten your life, such as cancer that has spread, or make study activities unsafe, such as Parkinson's disease or muscle, bone, or joint problems.
  • You have hearing or vision problems that keep you from taking part.
  • You currently misuse alcohol or drugs.
  • You are doing brain training or using treatments expected to strongly affect how the brain changes and adapts. Examples include psychedelic drugs, certain Alzheimer's medicines called cholinesterase inhibitors, or high doses of medicines that make you sleepy.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Hispanic/Latino * Age 65 and older * Male, female, or non-binary * Community living * Medically stable and willing to undergo the study procedures * No extensive mindfulness training experience Exclusion Criteria: * Clinically unstable psychiatric disorder that requires immediate treatment (e.g., ECT) * Medical conditions suggesting significantly shortened lifespan (e.g., metastatic cancer) or prohibiting safe participation in the interventions/assessments (e.g., Parkinson's disease, musculoskeletal conditions) * Sensory impairment (hearing, vision) preventing participation * Current alcohol or substance abuse * Current/concurrent cognitive training known to affect neuroplasticity (e.g., brain-training programs), or other interventions expected to affect neuroplasticity significantly (e.g., psychedelics, cholinesterase inhibitors, high-dose sedatives).

Study sites (1)

MO